Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
- LDP Generic League to Soon Draw Up Proposal towards Honebuto Policy
April 9, 2024
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
- Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
- Japan Govt Ends COVID Vaccine Supply as Emergency Program Winds Up
April 3, 2024
- Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
- Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
- Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
- Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
- Drug Makers in Japan Asked to Create Pediatric Development Plans from April
April 1, 2024
- MHLW Defines “Long-Listed Products” towards Rollout of New Coverage Rule
April 1, 2024
- Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
- LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
- Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
- Japan Diet Passes FY2024 Budget, Record Social Security Spending
March 29, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…